DPA
TARA icon

Devon Park Associates’s Protara Therapeutics TARA Stock Holding History

Devon Park Associates’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-8,143
Closed -$3.79M – 3
2015
Q1 		$3.79M Hold
8,143
– – 2.79% 4
2014
Q4 		$3.39M Buy
+8,143
New +$3.28M 2.58% 4

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Devon Park Associates's TARA Position: Q2 2015 in Review

Devon Park Associates sold out of Protara Therapeutics (TARA) in Q2 2015, closing a stake of 8,143 shares — an estimated $3.79M sold.

Devon Park Associates first reported a position in TARA in Q4 2014 and held it in 2 quarters. The position peaked at $3.79M in Q1 2015. 48 funds tracked by Wall St. Rank hold TARA as of Q2 2015.

  • Devon Park Associates reported no remaining Protara Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Devon Park Associates sold 8,143 Protara Therapeutics shares in Q2 2015, an estimated $3.79M.
  • Devon Park Associates first reported a position in Protara Therapeutics in Q4 2014 and held it in 2 quarters.
  • Devon Park Associates's Protara Therapeutics position peaked at $3.79M in Q1 2015.
  • 48 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2015.

Based on Devon Park Associates's 13F filing for Q2 2015, filed 14 Aug 2015.